Across various social media platforms, a surge in discussions and personal accounts has highlighted a surprising potential side effect of certain medications primarily used to treat Type 2 diabetes and assist with weight loss: unexpected pregnancies. Women are reporting that while taking Glucagon-like peptide-1 (GLP-1) drugs such as Ozempic, semaglutide, Mounjaro, and similar medications, they have experienced unplanned pregnancies, a phenomenon that is becoming increasingly associated with the term “Ozempic babies.”
These accounts are primarily anecdotal, with no concrete data yet to indicate the prevalence of this occurrence. Nevertheless, the phenomenon has prompted discussion within the medical community and among those using GLP-1 drugs. Deb Oliviara, a user of Ozempic, shared her experience of becoming pregnant while on the medication, stating, “I was three weeks along when I found out… I am now 3 months pregnant, and baby is doing amazing.” Another user referenced her success in conceiving after a decade of struggling with polycystic ovary syndrome (PCOS), a condition often linked to infertility.
Experts posit that significant weight loss, which is a common effect of GLP-1 medications, can alter fertility by potentially balancing hormones and improving insulin resistance, which may stimulate ovulation in individuals who were previously not ovulating. For instance, Lora Shahine, a reproductive endocrinologist, highlights that the “hormonal access clicks back in, and all of a sudden they start ovulating again.” Stephanie Fein, an internist, adds that even a modest weight reduction of 5 to 10 percent can enhance the likelihood of conception.
Complicating matters, GLP-1 drugs are known to slow gastric emptying, which may affect the absorption of oral contraceptives, rendering them less effective. This interaction has raised concerns regarding birth control failures while on the medication. William Dietz, a physician affiliated with the STOP Obesity Alliance, warns that this altered drug metabolism could mean “birth control medications are metabolized or ineffective.”
The potential risks to fetuses exposed to GLP-1 medications are not well-understood due to the exclusion of pregnant individuals or those intending to become pregnant from early clinical trials. According to a Novo Nordisk spokesperson, there “may be potential risks to the fetus from exposure to semaglutide during pregnancy.” Animal studies have likewise indicated possible negative outcomes, such as fetal abnormalities and growth issues. Pregnant women taking GLP-1 drugs for diabetes management are encouraged to discuss the benefits and risks with their healthcare provider.
Those taking GLP-1 medications for weight loss purposes and considering pregnancy are advised to discontinue the drug at least two months before attempting to conceive due to the potential, albeit not conclusively known, risks associated with these medications during early fetal development. For those using the medication and becoming pregnant, the immediate cessation of the drug and consultation with a medical professional are crucial steps.
Relevant articles:
– An Ozempic baby boom? Some GLP-1 users report unexpected pregnancies. Washington Post
– Does Ozempic Affect Fertility or Birth Control? everydayhealth.com
– Ozempic Babies: Weight Loss Drugs, Pregnancy Risks, Fertility Benefits today.com